Dimensional Fund Advisors’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,247,845
| Closed | -$65.8M | – | 3299 |
|
|
2026
Q1 | $65.8M | Buy |
1,247,845
+82
| +0% | +$3.37K | 0.01% | 1348 |
|
|
2025
Q4 | $50.4M | Sell |
1,247,763
-208,638
| -14% | -$4.82M | 0.01% | 1507 |
|
|
2025
Q3 | $10.9M | Sell |
1,456,401
-194,549
| -12% | -$1.24M | ﹤0.01% | 2271 |
|
|
2025
Q2 | $6.16M | Sell |
1,650,950
-55,251
| -3% | -$173K | ﹤0.01% | 2461 |
|
|
2025
Q1 | $4.71M | Buy |
1,706,201
+403,269
| +31% | +$1.65M | ﹤0.01% | 2510 |
|
|
2024
Q4 | $7.22M | Buy |
1,302,932
+673,570
| +107% | +$4.56M | ﹤0.01% | 2425 |
|
|
2024
Q3 | $5.25M | Buy |
629,362
+257,470
| +69% | +$2.12M | ﹤0.01% | 2510 |
|
|
2024
Q2 | $2.53M | Buy |
371,892
+31,875
| +9% | +$193K | ﹤0.01% | 2709 |
|
|
2024
Q1 | $2.23M | Buy |
340,017
+262,192
| +337% | +$1.71M | ﹤0.01% | 2768 |
|
|
2023
Q4 | $506K | Sell |
77,825
-10,887
| -12% | -$57.6K | ﹤0.01% | 3042 |
|
|
2023
Q3 | $446K | Sell |
88,712
-149,652
| -63% | -$950K | ﹤0.01% | 3065 |
|
|
2023
Q2 | $2.09M | Buy |
238,364
+1,253
| +0.5% | +$14.6K | ﹤0.01% | 2774 |
|
|
2023
Q1 | $2.81M | Buy |
+237,111
| New | +$2.27M | ﹤0.01% | 2651 |
|
|
2022
Q3 | $196K | Buy |
+33,312
| New | +$124K | ﹤0.01% | 3241 |
|
Other funds holding TERN
Dimensional Fund Advisors's TERN Position: Q2 2026 in Review
Dimensional Fund Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,247,845 shares — an estimated $65.8M sold.
Dimensional Fund Advisors first reported a position in TERN in Q3 2022 and held it in 14 quarters. The position peaked at $65.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Dimensional Fund Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Dimensional Fund Advisors sold 1,247,845 Terns Pharmaceuticals shares in Q2 2026, an estimated $65.8M.
- Dimensional Fund Advisors first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 14 quarters.
- Dimensional Fund Advisors's Terns Pharmaceuticals position peaked at $65.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.